Mesoblast (NASDAQ:MESO) Rating Increased to Strong-Buy at Cantor Fitzgerald

Cantor Fitzgerald upgraded shares of Mesoblast (NASDAQ:MESO) to a strong-buy rating in a report released on Monday,Zacks.com reports. Cantor Fitzgerald also issued estimates for Mesoblast’s FY2025 earnings at ($0.71) EPS.

Several other equities research analysts have also recently weighed in on the company. Piper Sandler restated an “overweight” rating and set a $24.00 target price (up from $15.00) on shares of Mesoblast in a research note on Friday, February 7th. Jefferies Financial Group downgraded Mesoblast from a “buy” rating to a “hold” rating in a research report on Monday, December 23rd. One analyst has rated the stock with a sell rating, one has given a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $18.00.

Mesoblast Stock Down 0.7 %

Shares of NASDAQ:MESO opened at $11.82 on Monday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.18 and a current ratio of 1.18. The firm has a 50 day moving average of $15.97 and a 200-day moving average of $13.28. Mesoblast has a 12 month low of $4.60 and a 12 month high of $22.00.

Institutional Trading of Mesoblast

Hedge funds and other institutional investors have recently modified their holdings of the stock. Lindbrook Capital LLC boosted its holdings in shares of Mesoblast by 70.9% during the 4th quarter. Lindbrook Capital LLC now owns 2,172 shares of the company’s stock valued at $43,000 after acquiring an additional 901 shares in the last quarter. GAMMA Investing LLC raised its position in Mesoblast by 22.1% in the fourth quarter. GAMMA Investing LLC now owns 6,711 shares of the company’s stock valued at $133,000 after purchasing an additional 1,213 shares during the last quarter. R Squared Ltd acquired a new stake in shares of Mesoblast during the fourth quarter valued at about $30,000. Prosperity Wealth Management Inc. grew its holdings in shares of Mesoblast by 2.0% during the fourth quarter. Prosperity Wealth Management Inc. now owns 93,245 shares of the company’s stock worth $1,846,000 after purchasing an additional 1,795 shares during the last quarter. Finally, Quadrant Capital Group LLC increased its stake in shares of Mesoblast by 41.1% in the fourth quarter. Quadrant Capital Group LLC now owns 6,496 shares of the company’s stock valued at $129,000 after buying an additional 1,891 shares during the period. Institutional investors own 1.43% of the company’s stock.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.